Leerink Partnrs Issues Negative Forecast for TNDM Earnings

Key Points

• Leerink Partners has downgraded their earnings forecast for Tandem Diabetes Care (TNDM), now predicting a loss of $0.41 per share for Q3 2025, down from a previous estimate of $0.32.
• Tandem Diabetes Care reported Q2 2025 earnings of ($0.48) per share, which was below analysts' expectations of ($0.40) per share, despite a year-over-year revenue increase of 8.5%.
• Several brokerages, including Wells Fargo and Citigroup, have lowered their target prices for the stock, reflecting a generally pessimistic outlook among analysts, with an average target price now at $23.43.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) - Investment analysts at Leerink Partnrs decreased their Q3 2025 earnings estimates for shares of Tandem Diabetes Care in a research note issued to investors on Wednesday, August 6th. Leerink Partnrs analyst M. Kratky now anticipates that the medical device company will post earnings per share of ($0.41) for the quarter, down from their previous forecast of ($0.32). The consensus estimate for Tandem Diabetes Care's current full-year earnings is ($1.68) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care's Q4 2025 earnings at $0.05 EPS, FY2026 earnings at ($0.66) EPS, FY2027 earnings at ($0.04) EPS and FY2029 earnings at $1.10 EPS.

A number of other research analysts have also weighed in on the stock. Lake Street Capital lowered shares of Tandem Diabetes Care from a "buy" rating to a "hold" rating and reduced their price objective for the company from $75.00 to $12.00 in a research note on Monday. Wells Fargo & Company reduced their price objective on shares of Tandem Diabetes Care from $20.00 to $13.00 and set an "equal weight" rating for the company in a research note on Thursday, August 7th. Truist Financial assumed coverage on shares of Tandem Diabetes Care in a research note on Monday, June 16th. They issued a "hold" rating and a $24.00 price objective for the company. Royal Bank Of Canada reduced their price target on shares of Tandem Diabetes Care from $45.00 to $25.00 and set an "outperform" rating for the company in a research report on Thursday, August 7th. Finally, Robert W. Baird reduced their price target on shares of Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating for the company in a research report on Thursday, May 1st. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $22.67.

Tandem Diabetes Care Stock Performance

Tandem Diabetes Care stock traded up $0.02 during mid-day trading on Monday, reaching $11.13. The company's stock had a trading volume of 1,734,947 shares, compared to its average volume of 1,703,210. Tandem Diabetes Care has a 12-month low of $9.98 and a 12-month high of $47.60. The company has a market capitalization of $752.12 million, a P/E ratio of -3.61 and a beta of 1.46. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.88 and a current ratio of 2.44. The firm's fifty day moving average price is $17.17 and its two-hundred day moving average price is $21.10.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The medical device company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.08). Tandem Diabetes Care had a negative return on equity of 65.40% and a negative net margin of 20.51%. The company had revenue of $240.68 million for the quarter, compared to analysts' expectations of $238.39 million. During the same quarter in the previous year, the business earned ($0.47) EPS. The company's revenue for the quarter was up 8.5% on a year-over-year basis.

Insiders Place Their Bets

In related news, CFO Leigh Vosseller acquired 13,720 shares of the company's stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $10.89 per share, with a total value of $149,410.80. Following the acquisition, the chief financial officer owned 25,580 shares of the company's stock, valued at approximately $278,566.20. The trade was a 115.68% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John F. Sheridan purchased 10,000 shares of the stock in a transaction on Monday, August 11th. The stock was acquired at an average cost of $10.23 per share, with a total value of $102,300.00. Following the completion of the purchase, the chief executive officer directly owned 106,327 shares of the company's stock, valued at $1,087,725.21. The trade was a 10.38% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.90% of the company's stock.

Institutional Trading of Tandem Diabetes Care

Hedge funds have recently added to or reduced their stakes in the business. Assetmark Inc. lifted its stake in Tandem Diabetes Care by 42.9% in the first quarter. Assetmark Inc. now owns 1,750 shares of the medical device company's stock worth $34,000 after purchasing an additional 525 shares during the last quarter. NBC Securities Inc. bought a new position in shares of Tandem Diabetes Care during the first quarter valued at about $37,000. CWM LLC raised its stake in shares of Tandem Diabetes Care by 262.6% during the second quarter. CWM LLC now owns 2,796 shares of the medical device company's stock valued at $52,000 after acquiring an additional 2,025 shares during the last quarter. Brooklyn Investment Group raised its stake in shares of Tandem Diabetes Care by 417.8% during the first quarter. Brooklyn Investment Group now owns 3,397 shares of the medical device company's stock valued at $65,000 after acquiring an additional 2,741 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its stake in shares of Tandem Diabetes Care by 186.9% during the second quarter. Nisa Investment Advisors LLC now owns 4,171 shares of the medical device company's stock valued at $78,000 after acquiring an additional 2,717 shares during the last quarter.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.